Articles |
From the Department of Medicine and Research Center (J.F., G.-R.L., Z.W., S.N.), Montreal (Canada) Heart Institute; the Department of Medicine (G.-R.L., Z.W., S.N.), University of Montreal (Canada); the Department of Pharmacology and Therapeutics, McGill University (S.N.), Montreal, Quebec, Canada; and the Rammelkamp Center for Research (B.W.), MetroHealth Campus, Case Western Reserve University, Cleveland, Ohio.
Correspondence to Stanley Nattel, MD, Montreal Heart Institute, 5000 Belanger St East, Montreal, Quebec H1T 1C8, Canada.
| Abstract |
|---|
|
|
|---|
50%) reduction in IKur, whether measured
by step current at the end of a 400-millisecond depolarizing pulse,
tail current at -20 mV, or current sensitive to a concentration of
4-aminopyridine (50 µmol/L) that is highly selective for
IKur, compared with control cells or cells exposed to
mismatch oligodeoxynucleo-tides. In contrast, Ito was
not different among the three experimental groups. When cultured human
ventricular myocytes were exposed to Kv1.5 antisense
oligodeoxynucleotides with the same controls, no changes occurred in
either Ito or the sustained current at the end of a
depolarizing pulse. We conclude that Kv1.5 channel subunits are
essential to the expression of IKur and do not play a role
in Ito in cultured human atrial myocytes. These studies
provide the first direct evidence with an antisense approach for the
equivalence between a macroscopic cardiac K+ current and a
cloned K+ channel subunit and offer insights into the
molecular electrophysiology of the human heart.
Key Words: K+ channel antiarrhythmic drug heart electrophysiology cardiac action potential molecular genetics
| Introduction |
|---|
|
|
|---|
The molecular basis of Ito in the human heart is also an
unresolved issue. Although an inactivating Shaker-type Kv1.4
K+ channel subunit with 4-AP sensitivity similar to that of
human Ito was cloned from the human heart several years
ago,9 its reactivation properties do not match those of
human Ito.10 Among the possible explanations
of this discrepancy are the existence of heterotetrameric channels
involving Kv1.4 subunits and a slowly inactivating channel subunit like
Kv1.511 or the introduction of rapid inactivation by a
ß-peptide12 13 14 15 to a slowly inactivating
-subunit like
Kv1.5. Therefore, in addition to being a candidate to underlie
IKur in the human heart, Kv1.5 may also be an important
part of the channel underlying Ito.
Antisense oligodeoxynucleotides inhibit the production of proteins corresponding to the mRNA against which they are directed, acting in complex ways to affect mRNA expression and/or translation.16 They have recently been used to demonstrate the relationship between Kv1.5 channel subunits and K+ currents in pituitary cell lines.17 We have reported the characteristics of several ionic currents in adult human atrial myocytes maintained in primary culture for up to 7 days.18 Both IKur and Ito are readily recorded and have stable properties from the first through the seventh day in culture.18 The present study was designed to determine the effects of antisense oligodeoxynucleotides on the expression of IKur and Ito in cultured human atrial myocytes. To accomplish this, we compared cells incubated in the presence of either antisense octodecameric phosphoro-thioate oligodeoxynucleotides or control oligodeoxynucleo-tides with mismatch mutations (administered in a blinded fashion to avoid bias), along with cells maintained in control culture medium, to which only the vehicle for oligodeoxynucleotides was added.
| Materials and Methods |
|---|
|
|
|---|
Myocyte Isolation
Specimens of human right atrial appendage were obtained from the
hearts of 9 patients (mean age, 61 years; range, 44 to 73 years)
undergoing aortocoronary bypass surgery. The atria were all grossly
normal and from patients without heart failure or atrial arrhythmias.
The procedure for obtaining the tissue was approved by the Ethics
Committee of the Montreal Heart Institute. The samples were quickly
immersed in oxygenated (100% O2) nominally
Ca2+-free Tyrode's solution containing (mmol/L) NaCl
126.0, KCl 5.4, MgCl2 1.0, NaH2PO4
0.33, dextrose 10, and HEPES (Sigma Chemical Co) 10; pH was adjusted to
7.4 with NaOH. The tissue was immediately transported to the
laboratory, where further processing was performed at 37°C. The
specimens were diced into cubic chunks (1 mm3), and
placed in a 25-mL flask containing 10 mL of the Ca2+-free
Tyrode's solution. The tissue was gently agitated by continuous
bubbling with 100% O2 and stirring with a magnetic bar.
After 5 minutes, the chunks were reincubated in a similar solution
containing 390 U/mL collagenase (CLS II, Worthington Biochemical) and 4
U/mL protease (type XXIV, Sigma). The first supernatant was removed
after 45 minutes, and the tissue was reincubated in a fresh
enzyme-containing solution. Microscopic examination was performed every
15 minutes, and when the yield appeared to be maximal, the chunks were
suspended in a storage solution containing (mmol/L) KCl 20,
KH2PO4 10, glucose 10, glutamic acid 70,
ß-hydroxybutyric acid 10, taurine 10, EGTA 10, and albumin 1% (pH
was adjusted to 7.4 with KOH) and gently pipetted. The remaining tissue
chunks were then removed, the cell suspension was centrifuged at 250
rpm for 5 minutes, and the pellet was removed for culture. All
procedures were performed with aseptic techniques.
Human ventricular myocytes were obtained from explanted right ventricles of two cardiac transplant recipients (aged 23 and 58 years) with the use of methods previously described in detail.8 In brief, a portion of the right ventricular free wall was perfused via a coronary artery, initially with Ca2+-free Tyrode's solution (for 20 to 30 minutes) and then with a similar solution containing 200 to 300 U/mL of collagenase (CLS II, Worthington). The digested tissue was cut into small pieces (1 to 2 mm3) and placed in the storage solution described above, and the cells were obtained by gentle trituration with a Pasteur pipette. Both patients were suffering from idiopathic congestive cardiomyopathies, and the right ventricle was macroscopically normal in both cases. Microscopic examination showed interstitial fibrosis and mononuclear cell infiltrates in both.
Cell Culture and Exposure to Oligodeoxynucleotides
Cells were cultured in Petri dishes (35-mm, Nunc Co) containing
medium 199 with 10% fetal bovine serum (both from GIBCO-BRL)
supplemented with sodium penicillin G (1 U/mL) and streptomycin sulfate
(1 µg/mL, GIBCO-BRL). Cells were allowed to adhere to the bottom of
the Petri dish and maintained in the medium at 37°C in a humidified,
5% CO2-enriched atmosphere. Oligodeoxynucleotide treatment
was started 24 hours after the onset of culture. Three groups of
cultured cells were studied in all series of experiments: one (referred
to in this article as the "control group") was exposed to the
vehicle for oligodeoxynucleotides (sterilized distilled water with the
same volume as for oligodeoxynucleotide groups), a second group was
exposed to mismatch oligodeoxynucleotides (mismatch oligo A and/or
mismatch oligo B), and a third group was exposed to antisense
(antisense oligo A and/or antisense oligo B) oligodeoxynucleotides. The
oligodeoxynucleotides were prepared by one investigator (B.W.), who
provided stocks that were coded so that the investigators performing
culture, treatment, and electrophysiological study were unaware of
treatment allocation until experiments and data analyses were
completed. For each treatment, the growth medium was removed, and
oligodeoxynucleotides or vehicle in medium without serum was added to
the cells. After a 30-minute incubation at 37°C, heat-inactivated
serum (final concentration, 10%) was returned to the medium. The same
procedure was used for all groups and repeated every 12 hours for 48
hours. Patch-clamp experiments were performed after 48 hours of
treatment.
Four series of experiments were performed. In the first series, cultured atrial cells from five hearts were exposed to 5 µmol/L antisense oligodeoxynucleotides (equal quantities of antisense oligo A and B), 5 µmol/L mismatch oligodeoxynucleotides (equal quantities of mismatch oligo A and B), or equal volumes of vehicle. In the second series, atrial cells from two hearts were exposed to the same solutions, but at a lower concentration (2 µmol/L). Because of possible nonspecific effects of oligodeoxynucleotides containing four successive guanine bases (as in antisense oligo A), a third series of experiments was performed in which atrial cells from two hearts were exposed to 5 µmol/L antisense oligo B, 5 µmol/L mismatch oligo B, or an equal quantity of vehicle. In the final series of experiments, cultured ventricular myocytes were exposed to 5 µmol/L antisense oligo A and B, 5 µmol/L mismatch oligo A and B, or equal volumes of vehicle. In each series of experiments, results were obtained with approximately equal numbers of cells from each heart under each condition studied. This was essential to avoid distortion of results by interpreparation variability in current amplitudes and to ensure that the results were representative of all hearts for each condition.
Solutions and Drugs
The extracellular solution for patch-clamp studies contained
(mmol/L) choline chloride 126, KCl 5.4, MgCl2 1.0,
CaCl2 1.0, HEPES 5, NaH2PO4 0.33,
and dextrose 10. The pipette solution contained (mmol/L ) potassium
aspartate 110, KCl 20, MgCl2 1.0, HEPES 5, EGTA 5, Mg-ATP
5, GTP 0.1, and Na2-phosphocreatine 5. The pH of external
and internal solutions was adjusted to 7.3 with the use of CsOH.
CdCl2 (200 µmol/L) was used to block
Ca2+ current. 4-AP was prepared as a stock solution (1
mol/L) in distilled water, with pH adjusted to 7.3 with HCl. All
chemicals and drugs were obtained from Sigma.
Data Acquisition and Analysis
The whole-cell patch-clamp technique was used to record ionic
currents in the voltage-clamp mode. The 35-mm Petri dishes used for
cell culture also served as baths for voltage-clamp experiments. All
experiments were conducted at room temperature (20°C to 23°C). We
used borosilicate glass electrodes (outer diameter, 1.0 mm) with
tip resistances of 2.5 to 5 M
when filled. Currents were recorded
with an Axopatch 1-D amplifier (Axon Instruments). Command pulses were
generated by a 12-bit digital-to-analog converter controlled by pClamp
software (Axon). Recordings were low passfiltered at 1 kHz. Currents
were digitized (model TM 125, Scientific Solutions) and stored on the
hard disk of a personal computer.
Junction potentials were zeroed before formation of the
membrane-pipette seal in 1 mmol/L Ca2+containing
Tyrode's solution. Mean seal resistance averaged 19.3±2.8 G
(n=30). Several minutes after seal formation, the membrane was ruptured
by gentle suction to establish the whole-cell configuration for voltage
clamping. The series resistance was electrically compensated to
minimize the duration of the capacitive surge on the current record.
Series resistance along the clamp circuit was estimated by dividing the
time constant obtained by fitting the decay of the capacitive transient
by the calculated cell membrane capacitance (the time integral of the
capacitive surge measured in response to 5-mV hyperpolarizing steps
from a holding potential of -60 mV divided by the voltage drop). The
decay of the capacitive surge was well fit by a single-exponential
relation. Cell capacitance averaged 30.2±2.8 pF (n=30 ) and 28.7±2.6
pF (n=30) before and after compensation, respectively, in atrial
myocytes and 93.6±7.2 pF (n=20) and 90.5±6.8 pF (n=20) in ventricular
myocytes. The capacitive time constant averaged 162.8±20.3 and
68.9±7.3 microseconds before and after compensation, respectively, in
atrial myocytes and 851±68 and 233±19 microseconds in ventricular
myocytes. Series resistance averaged 5.6±0.8 and 2.5±0.3 M
before
and after compensation, respectively, in atrial myocytes and 8.9±0.6
and 2.7±0.2 M
in ventricular myocytes. Leak currents were small,
and no correction for leak currents was applied.
The amplitude of Ito was measured as the difference between the peak of Ito and the current level at the end of the pulse. Isus was measured as the amplitude of the current at the end of the test pulse relative to the zero current level. Tail currents were measured as the time-dependent deactivating component at -20 mV after an activating pulse to a more positive potential.
Comparisons among groups were performed by ANOVA with Scheffé's contrasts. A two-tailed probability of 5% was taken to indicate statistical significance. Group data are presented as mean±SEM. Nonlinear curve fitting (Marquardt's procedure) was performed using Clampfit in pClamp.
| Results |
|---|
|
|
|---|
Fig 1A
shows currents recorded from 39 randomly selected
control cells (of a total of 55 studied) upon 400-millisecond
depolarization from a holding potential of -80 to +50 mV. Cells showed
a rapidly activating and inactivating Ito component of
variable magnitude, with a residual component at the end of the pulse,
which we have previously shown corresponds largely to
IKur.2 18 Corresponding results obtained from
a random sample of 39 cells (of a total of 55) incubated in combined
antisense oligo A and B (5 µmol/L) are shown in Fig 1B
, and
results from 39 randomly sampled cells exposed to combined mismatch
oligo A and B (5 µmol/L) are shown in Fig 1C
. When currents from
all 55 cells in each group were averaged, the results shown in Fig 1D
were obtained. The mean current-time relations for control cells and
those exposed to mismatch oligodeoxynucleotides could be superimposed,
but the mean current recorded in cells exposed to antisense
oligodeoxynucleotides showed a parallel displacement to smaller values.
Fig 1E
shows the current-time relation when mean currents in cells
exposed to antisense oligodeoxynucleotides were subtracted from
corresponding currents recorded in control cells. The subtracted
current has the rapid activation kinetics and minimal inactivation over
400 milliseconds that is typical of IKur.2
Results obtained by subtracting mean currents in cells exposed to
mismatch oligodeoxynucleotides from those in control cells are shown in
Fig 1F
and indicate that exposure to mismatch oligodeoxynucleotides did
not significantly affect currents recorded with this protocol.
|
For each of the cells studied, we calculated the amplitude of
Ito (difference between peak and end-pulse current upon
depolarization from -80 to +50 mV) and the amplitude of sustained
end-pulse current relative to the zero current level (Isus,
an index of IKur2 ). The results of this
analysis are shown in Fig 2
(left panels). Antisense
oligodeoxynucleotides (5 µmol/L) significantly reduced the
amplitude of Isus (Fig 2A
) but had no effect on
Ito (Fig 2B
). Mismatch oligodeoxynucleotides did not affect
either Isus or IKur. The same approaches
described above were used to study a lower concentration (2
µmol/L) of combined oligodeoxynucleotides. Results were obtained for
23 cells under each condition (Fig 2C
and 2D
) and were qualitatively
the same as those with the higher oligodeoxynucleotide concentration
shown in Figs 1
, 2A
, and 2B
. These data indicate that antisense (but
not mismatch) oligodeoxynucleotides significantly inhibited
Isus without altering Ito.
|
Currents recorded in cultured human atrial cells upon depolarization
from a holding potential of -80 mV typically contain both
Ito and IKur. In order to evaluate directly the
changes in IKur, the latter was isolated with the use of a
holding potential of -50 mV and a depolarizing prepulse (100
milliseconds) to +40 mV at 10 milliseconds before a 180-millisecond
test pulse, as previously reported.2 A 120-millisecond
repolarization to -20 mV was applied after the test pulse in order to
record IKur tail currents. As in the left panels of Fig 1
,
the left panels of Fig 3
show recordings from multiple
cells in each group randomly selected from all 51 cells per group
exposed to 5 µmol/L combined oligodeoxynucleotides studied with
this protocol. Results from 18 control cells are shown in Fig 3A
. The
rapid activation, lack of inactivation, and small tail currents typical
of IKur are clear. Currents are substantially smaller in 19
cells exposed to antisense (Fig 3B
) and not obviously different from
control in 18 cells exposed to mismatch oligodeoxynucleotides (Fig 3C
).
Because of their relatively small amplitude, IKur tail
currents are hard to observe in the left panels of Fig 3
. The right
panels show tail currents from the same cells and protocol as in the
left panels, but on an expanded current and time scale. Tail currents
were recorded in all vehicle-exposed control cells (Fig 3D
), albeit
with varying amplitude. Cells exposed to antisense
oligodeoxynucleotides similarly showed tail currents (Fig 3E
), but of
diminished size. Tail currents in cells exposed to mismatch
oligodeoxynucleotides (Fig 3F
) resembled those in control cells exposed
to vehicle (Fig 3D
).
|
Average current-time relations recorded with the use of the protocol in
Fig 3
in all 51 cells from each group are shown in Fig 4A
. Cells exposed to vehicle and mismatch
oligodeoxynucleotides have similar current-time relations, but currents
are substantially reduced in antisense-exposed cells.
Antisense-sensitive mean currents obtained by digital subtraction are
shown in Fig 4B
and indicate that the current inhibited by antisense is
rapidly activating, shows little inactivation, and has small tail
currents upon repolarization. Fig 4C
shows mean±SEM values of
IKur step current in each group of cells exposed to 5
µmol/L combined oligodeoxynucleo-tides or vehicle. Antisense
oligodeoxynucleotides significantly reduced IKur, whereas
mismatch oligodeoxynucleotides had no effect. Mean IKur
tail currents from all 51 cells in each group are shown on an expanded
current and time scale in Fig 4D
and show that antisense
oligodeoxynucleotides inhibited tail current without altering its
overall kinetics. This point is further made by the average current
obtained by digitally subtracting mean tail currents from cells exposed
to antisense from those incubated in vehicle (Fig 4E
). Overall
mean±SEM tail current amplitudes from each group are shown in Fig 4F
and show that IKur tail currents were significantly smaller
in cells exposed to antisense than in the other two groups.
|
Fig 5
illustrates the voltage dependence of
Isus and Ito in the three groups of cells used
to study the effects of combined 5 µmol/L oligodeoxynucleotides.
Currents were elicited by 400-millisecond depolarizing pulses from -80
mV at 0.1 Hz. Isus, reflecting IKur, was
significantly reduced in cells exposed to antisense at all voltages
positive to 0 mV and was not significantly different at any voltage in
cells exposed to vehicle compared with those exposed to mismatch
oligodeoxynucleotides (Fig 5A
). In contrast, Ito was the
same at all voltages in all groups (Fig 5B
).
|
As an additional test of the effects of antisense on IKur, we determined the density of 50 µmol/L 4-APsensitive current in five cells from each group used to study the effects of 5 µmol/L combined oligodeoxynucleotides. Cells were depolarized from a holding potential of -80 to +50 mV before and after superfusion of 4-AP, at a concentration (50 µmol/L) that we have previously shown specifically inhibits IKur in human atrial myocytes.2 18 Digital subtraction of recordings in the presence of 4-AP from those before 4-AP was used to obtain 4-APsensitive currents, which were then normalized to cell capacitance to obtain 4-APsensitive current density. The latter averaged 6.8±0.8 pA/pF in control vehicle-treated cells, 3.1±0.4 pA/pF in antisense-treated cells, and 6.5±0.7 pA/pF in cells exposed to mismatch oligodeoxynucleotides (P=NS for control versus mismatch oligodeoxynucleotides; P<.01 for antisense versus the other two groups).
Studies of Atrial Myocytes Exposed to Single
Oligodeoxynucleotides
Because antisense oligo A contains four sequential guanine bases,
a sequence that can have nonspecific effects, we incubated groups of
cells with only antisense oligo B, its corresponding mismatch
oligodeoxynucleotide (mismatch oligo B), or vehicle. Cells exposed to
5 µmol/L antisense oligo B (n=25) showed significant decreases
in IKur when compared with the same number of cells exposed
to mismatch oligo B or vehicle control cells. Fig 6A
shows mean amplitudes of IKur tail current, measured with
the use of the protocol illustrated in Fig 3
. Tail currents were
50% smaller in cells exposed to antisense compared with the other
two groups. In contrast, Ito was not altered by exposure to
antisense (Fig 6B
, n=25 cells per group).
|
Studies of Ventricular Myocytes
Fig 7A
shows typical currents recorded upon
depolarization to various voltages from a holding potential of -80 mV
in a cultured human ventricular myocyte exposed to vehicle. A sizable
Ito is observed, along with small sustained currents at the
end of a depolarizing pulse. Exposure to 5 µmol/L combined
antisense oligo A and B (Fig 7B
) or equivalent concentrations of
mismatch oligo A and B (Fig 7C
) did not appreciably alter current
recordings. Mean data for current densities in 13 cultured human
ventricular myocytes exposed to antisense, 14 ventricular myocytes
exposed to mismatch oligodeoxynucleotides, and 14 vehicle controls are
shown in Fig 7D
(for Isus) and Fig 7E
(for
Ito). In contrast to results in human atrial myocytes,
antisense had no measurable effects on Isus density in
ventricular cells.
|
| Discussion |
|---|
|
|
|---|
Relevance to Understanding the Molecular Basis of Human
Cardiac Electrophysiology
The first two time-dependent K+ channel subunits to be
cloned from the human heart were initially designated HK1 and
HK29 and correspond to Kv1.4 and Kv1.5 channels according
to the present convention.19 More recently, clones
designated HERG and minK or IsK have
been discovered in human hearts.20 21 Functional
similarities have been demonstrated between currents carried by
channels encoded by human Kv1.4, Kv1.5, HERG, and
IsK and cardiac Ito, IKur,
IKr, and IKs,
respectively.2 3 4 8 10 22 23 Despite these functional
similarities, discrepancies remain, such as the different recovery time
courses of Kv1.4 and human cardiac Ito10 24
and the apparent differences in inactivation properties between Kv1.5
and IKur.2 4 A variety of criteria have been
suggested by Tamkun et al1 for identifying a native
current definitively with a cloned channel subunit. These include (1)
similar biophysical properties, (2) similar pharmacological responses,
(3) immunohistochemical evidence for the presence in the membrane of
protein encoded by the putative cDNA clone, (4) an ability to suppress
channel function with isoform-specific antibodies to channel subunit
protein, (5) affinity purification to confirm protein composition in
terms of accessory subunits and heterotetramer formation, and (6)
elimination of the function of the macroscopic current by deletion of
the cloned channel gene in a transgenic model. With respect to the
relationship between human IKur and Kv1.5,
electrophysiological evidence to support criteria 1 and 2 has been
obtained.2 3 4 5 6 25 A recent publication indicates the
presence of Kv1.5-encoded protein in human cardiac cell membranes on
the basis of immunohistochemical techniques, thus satisfying the third
criterion.7 Physiological evidence of the type envisioned
by criteria 4 and 6 has not been obtained: indeed, elimination of
IKur by creating transgenic humans with a deleted Kv1.5
gene (criterion 6) would seem to be unfeasible. The data in the present
study, however, speak to the objectives of criteria 4 and 6, by
demonstrating that antisense to Kv1.5 inhibited strongly
IKur expression in cultured human atrial myocytes. The lack
of effect of Kv1.5 antisense on sustained current in ventricular
myocytes is consistent with previous electrophysiological data
suggesting that IKur is absent in the human
ventricle.8 26 27
The molecular basis for Ito in human atrium is still uncertain. Although channels formed by Kv1.4 subunits have many properties like those of human cardiac Ito,10 their recovery from inactivation is two orders of magnitude slower than that of the native current.24 Therefore, it has been suggested that slowly inactivating channel subunits like Kv1.5 may be involved in carrying Ito, either via heterotetramer formation with inactivating channel subunits11 or by association with a ß-peptide.12 13 14 15 The present work argues against an essential role for Kv1.5 channel subunits in human cardiac Ito and is consistent with recent findings that Ito in the human heart may be carried by Kv4.3 channel subunits.28
In a recent study, Yang et al29 showed that antisense oligodeoxynucleotides directed against minK mRNA inhibits IKr in AT-1 cells, without changing levels of minK mRNA. The authors hypothesized either coassembly of minK with another protein (such as HERG) or an indirect role (such as anchoring of the channel protein complex to the cell surface) to explain their results. Given the strong similarities between currents expressed by Kv1.5 and IKur, the present results are much more likely to be due to direct inhibition of production of the protein encoded by Kv1.5, which underlies the IKur channel.
Potential Limitations
It is possible that the expression of ion channels is altered in
culture, and the extrapolation of results in a cultured system to ionic
currents in vivo must be tempered in this light. The voltage and time
dependence of IKur in culture are stable over time, as is
its 4-AP sensitivity, and resemble those of freshly isolated
cells.18 Our results can thus be related to the molecular
basis for IKur in vivo with confidence. On the other hand,
although Ito in cultured cells is stable over time, the
voltage- and time-dependent inactivation of Ito in cultured
human atrial myocytes is different from that in fresh
cells.18
We did not observe full suppression of IKur, even after 48 hours of exposure to antisense. These findings resemble previous observations with Kv1.5 antisense in a pituitary cell line.17 Possible explanations include a long half-life of Kv1.5 mRNA and/or protein, cellular mechanisms that permit some gene expression even in the presence of antisense, and a role for channel subunits from another gene in macroscopic IKur.
It would have been highly desirable to document changes in mRNA and/or Kv1.5 protein expression in the atrial cells exposed to antisense oligodeoxynucleo-tides. Unfortunately, given the small size of atrial samples, the low yield of cells with the "chunk" dissociation technique, and cell loss during solution changes in culture, the number of cells available at the end of the antisense exposure protocol was too small (rarely >30 cells) to permit quantitative detection of mRNA or protein levels. Because the techniques available to us for quantification of Kv1.5 mRNA and protein concentrations require a much larger amount of tissue, we did not attempt to apply these techniques to the antisense-treated or control cells. The specificity of the response to antisense is supported by the lack of effect of mismatch oligodeoxynucleotides, the lack of antisense-induced change in Ito, and the lack of effect on currents in ventricular myocytes.
There was considerable intercell variability in current amplitudes and
Ito kinetics (Fig 1
, left; Fig 3
, left). Because of this
variability, we showed data for a large sample of individual cells as
well as mean data. The underlying basis for this variable expression of
K+ currents is an interesting issue that goes beyond the
scope of the present study but must be considered in interpreting our
observations.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received May 28, 1996; accepted December 26, 1996.
| References |
|---|
|
|
|---|
subunits.
J Biol Chem. 1995;270:6272-6277. This article has been cited by other articles:
![]() |
M. Ander, V. B. Luzhkov, and J. Aqvist Ligand Binding to the Voltage-Gated Kv1.5 Potassium Channel in the Open State Docking and Computer Simulations of a Homology Model Biophys. J., February 1, 2008; 94(3): 820 - 831. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tsujimae, S. Murakami, and Y. Kurachi In silico study on the effects of IKur block kinetics on prolongation of human action potential after atrial fibrillation-induced electrical remodeling Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H793 - H800. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Eldstrom, Z. Wang, H. Xu, M. Pourrier, A. Ezrin, K. Gibson, and D. Fedida The Molecular Basis of High-Affinity Binding of the Antiarrhythmic Compound Vernakalant (RSD1235) to Kv1.5 Channels Mol. Pharmacol., December 1, 2007; 72(6): 1522 - 1534. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Fountain, A. Cheong, J. Li, N. Y. Dondas, F. Zeng, I. C. Wood, and D. J. Beech Kv1.5 potassium channel gene regulation by Sp1 transcription factor and oxidative stress Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2719 - H2725. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. P. McEwen, S. M. Schumacher, Q. Li, M. D. Benson, J. A. Iniguez-Lluhi, K. M. Van Genderen, and J. R. Martens Rab-GTPase-dependent Endocytic Recycling of KV1.5 in Atrial Myocytes J. Biol. Chem., October 5, 2007; 282(40): 29612 - 29620. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Abi-Char, A. Maguy, A. Coulombe, E. Balse, P. Ratajczak, J.-L. Samuel, S. Nattel, and S. N. Hatem Membrane cholesterol modulates Kv1.5 potassium channel distribution and function in rat cardiomyocytes J. Physiol., August 1, 2007; 582(3): 1205 - 1217. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Gaborit, S. Le Bouter, V. Szuts, A. Varro, D. Escande, S. Nattel, and S. Demolombe Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart J. Physiol., July 15, 2007; 582(2): 675 - 693. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. V. Remillard, D. D. Tigno, O. Platoshyn, E. D. Burg, E. E. Brevnova, D. Conger, A. Nicholson, B. K. Rana, R. N. Channick, L. J. Rubin, et al. Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension Am J Physiol Cell Physiol, May 1, 2007; 292(5): C1837 - C1853. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nattel, A. Maguy, S. Le Bouter, and Y.-H. Yeh Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation Physiol Rev, April 1, 2007; 87(2): 425 - 456. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Schotten, S. de Haan, S. Verheule, E. G.A. Harks, D. Frechen, E. Bodewig, M. Greiser, R. Ram, J. Maessen, M. Kelm, et al. Blockade of atrial-specific K+-currents increases atrial but not ventricular contractility by enhancing reverse mode Na+/Ca2+-exchange Cardiovasc Res, January 1, 2007; 73(1): 37 - 47. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Olson, A. E. Alekseev, X. K. Liu, S. Park, L. V. Zingman, M. Bienengraeber, S. Sattiraju, J. D. Ballew, A. Jahangir, and A. Terzic Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation Hum. Mol. Genet., July 15, 2006; 15(14): 2185 - 2191. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Ehrlich, S. H. Hohnloser, and S. Nattel Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence Eur. Heart J., March 1, 2006; 27(5): 512 - 518. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Maguy, T. E. Hebert, and S. Nattel Involvement of lipid rafts and caveolae in cardiac ion channel function Cardiovasc Res, March 1, 2006; 69(4): 798 - 807. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. H. Kwan, D. Fedida, and S. J. Kehl Single Channel Analysis Reveals Different Modes of Kv1.5 Gating Behavior Regulated by Changes of External pH Biophys. J., February 15, 2006; 90(4): 1212 - 1222. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Nerbonne and R. S. Kass Molecular Physiology of Cardiac Repolarization Physiol Rev, October 1, 2005; 85(4): 1205 - 1253. [Abstract] [Full Text] [PDF] |
||||